INT201652

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 2006
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 26
Total Number 27
Disease Relevance 26.79
Pain Relevance 2.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Tnfsf10)
Anatomy Link Frequency
macrophages 1
endothelial cell 1
melanocytes 1
epithelial cell 1
Tnfsf10 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 303 99.00 Very High Very High Very High
Inflammation 247 97.82 Very High Very High Very High
chemokine 76 97.44 Very High Very High Very High
Central nervous system 34 91.20 High High
Inflammatory response 34 86.56 High High
fortral 39 80.28 Quite High
agonist 12 79.68 Quite High
Infliximab 40 79.64 Quite High
Etanercept 39 79.32 Quite High
antagonist 17 73.60 Quite High
Disease Link Frequency Relevance Heat
Apoptosis 760 100.00 Very High Very High Very High
Melanoma 567 100.00 Very High Very High Very High
Cancer 564 100.00 Very High Very High Very High
Myocardial Infarction 265 99.84 Very High Very High Very High
Systemic Lupus Erythematosus 68 99.84 Very High Very High Very High
Death 178 99.76 Very High Very High Very High
Glioma 70 99.54 Very High Very High Very High
Disease 325 98.52 Very High Very High Very High
Toxicity 83 98.52 Very High Very High Very High
Malignant Neoplastic Disease 38 98.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
An important confirmation that serum TRAIL levels exert anti-inflammatory activity in clinically relevant conditions comes from a recent study in which it has been demonstrated that TRAIL levels progressively increase in the serum of patients after allogenic stem cell transplantation and show a protective effect against graft versus host disease and endothelial cell damage [32].
Positive_regulation (increase) of TRAIL in endothelial cell associated with inflammation and graft vs host disease
1) Confidence 0.68 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.96 Pain Relevance 0.17
After six months post AMI, serum TRAIL levels were further significantly increased, and no significant changes were observed at later time points (12 months; Figure 1).
Positive_regulation (increased) of TRAIL associated with myocardial infarction
2) Confidence 0.68 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.57 Pain Relevance 0
In fact, multiple delivery of Ad-stTRAIL to tumors resulted in sustained increase in stTRAIL levels in the tumor injection site (Figure 2C).
Positive_regulation (increase) of stTRAIL associated with cancer
3) Confidence 0.50 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2641005 Disease Relevance 1.17 Pain Relevance 0
Furthermore, TRAIL-apoptotic signalling in melanoma cells can be further increased by combinatorial treatment with rimcazole.
Positive_regulation (increased) of TRAIL-apoptotic associated with melanoma and apoptosis
4) Confidence 0.46 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 1.81 Pain Relevance 0.04
Previously, we and others have shown that upon binding to the respective target antigen, scFv:TRAIL fusion proteins can efficiently activate TRAIL-R2, whereas untargeted sTRAIL preparations have a markedly reduced capacity to activate TRAIL-R2 signaling.
Positive_regulation (activate) of TRAIL
5) Confidence 0.46 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.55 Pain Relevance 0
In the follow-up analysis of the same patients, we have observed a progressive increase of the TRAIL levels.
Positive_regulation (increase) of TRAIL
6) Confidence 0.45 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.51 Pain Relevance 0
In particular, at discharge (approximately 5–6 days after admission), the serum levels of TRAIL were already significantly increased, compared to the acute phase, but still significantly (p<0.01) lower with respect to normal controls (Figure 1).
Positive_regulation (increased) of TRAIL
7) Confidence 0.45 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2637972 Disease Relevance 0.51 Pain Relevance 0
TRAIL serum levels progressively increased at discharge, but normalized only at 6–12 months after AMI.
Positive_regulation (increased) of TRAIL associated with myocardial infarction
8) Confidence 0.45 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2637972 Disease Relevance 0.82 Pain Relevance 0.04
Anti-MCSP:TRAIL activity was further synergized by co-treatment with rimcazole, a ?
Positive_regulation (synergized) of TRAIL
9) Confidence 0.43 Published 2010 Journal Mol Cancer Section Abstract Doc Link PMC3000402 Disease Relevance 0.96 Pain Relevance 0.03
Thus, rimcazole appears to synergize the activity of anti-MCSP:TRAIL by promoting caspase-8 activation.
Spec (appears) Positive_regulation (synergize) of TRAIL
10) Confidence 0.43 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.64 Pain Relevance 0.16
Earlier studies have shown that tumor targeted delivery of TRAIL augments the tumor-specific activity of TRAIL, while not affecting the absence of toxicity on normal human cell types.
Positive_regulation (augments) of TRAIL associated with toxicity and cancer
11) Confidence 0.43 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.96 Pain Relevance 0
Indeed, although anti-MCSP:TRAIL strongly bound to MCSP on normal human melanocytes (Additional file 1, Figure S1D), no apoptosis was induced in melanocytes even when treatment was performed with 4 ?
Positive_regulation (induced) of TRAIL in melanocytes associated with apoptosis
12) Confidence 0.43 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.95 Pain Relevance 0
This dephosphorylation induced by anti-MCSP:TRAIL was detectable within 30 minutes and increased for up to 4 h after start of treatment (Figure 3E).
Positive_regulation (increased) of TRAIL
13) Confidence 0.43 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 0.20 Pain Relevance 0
Thus, anti-MCSP:TRAIL activity is strictly dependent on binding to cell surface-expressed MCSP on malignant cells.
Positive_regulation (dependent) of TRAIL associated with malignant neoplastic disease
14) Confidence 0.43 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 1.19 Pain Relevance 0
Of note, non-targeted sTRAIL has no intrinsic tumor-selective binding activity and is less efficient in cross-linking and activating TRAIL-R2 [21].
Positive_regulation (activating) of TRAIL associated with cancer
15) Confidence 0.37 Published 2010 Journal Mol Cancer Section Body Doc Link PMC3000402 Disease Relevance 1.76 Pain Relevance 0
In an attempt to establish a gene therapy approach to deliver stTRAIL to tissues efficiently, we inserted our stTRAIL expression cassette to ?
Positive_regulation (deliver) of stTRAIL
16) Confidence 0.36 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2641005 Disease Relevance 0.56 Pain Relevance 0
In tests using various glioma cells (Figure 2A), Ad-stTRAIL induced cell death in all except U373-MG and ACBRI371, both of which also showed significant resistance to recombinant TRAIL protein.
Positive_regulation (induced) of stTRAIL associated with death and glioma
17) Confidence 0.36 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2641005 Disease Relevance 0.87 Pain Relevance 0
Moreover, mRNA expression for TRAILR3 (TNFSF10C) and TRAILR4 (TNFSF10D), two decoy receptors for TRAIL, was also upregulated in SLE patients.
Positive_regulation (upregulated) of TRAIL associated with systemic lupus erythematosus
18) Confidence 0.28 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2768824 Disease Relevance 1.88 Pain Relevance 0.37
Urinary TRAIL levels were initially undetectable in BCG therapy patients, but levels increased after subsequent treatments.
Positive_regulation (increased) of TRAIL
19) Confidence 0.15 Published 2007 Journal BMC Immunol Section Body Doc Link PMC1891101 Disease Relevance 0.57 Pain Relevance 0.24
Urinary TRAIL levels were initially undetectable in BCG therapy patients, but levels increased after subsequent treatments.
Positive_regulation (undetectable) of TRAIL
20) Confidence 0.15 Published 2007 Journal BMC Immunol Section Body Doc Link PMC1891101 Disease Relevance 0.56 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox